Keywords: GlaxoSmithKline, USA, Tykerb, Lamictal, Approval, Breast cancer, Epilepsy, Employment,
US FDA clears new uses for two GlaxoSmithKline drugs; Tykerb and Lamictal; GSK set to announce 3,000 job cuts
Article | 1 February 2010
UK drug giant GlaxoSmithKline received two pieces of good news from the US Food and Drug Administration last Friday related to its breast cancer drug Tykerb (lapatinib) and Lamictal XR (lamotrigine), currently indicated for epilepsy and for maintenance treatment of bipolar I disorder.
On January 29, the FDA has granted accelerated approval for a new combination regimen using Tykerb as a first-line, all-oral treatment for women with metastatic breast cancer. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
